Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.

Saved in:
Bibliographic Details
Title: Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.
Authors: Elimova E; Department of Gastrointestinal Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: elena.elimova@uhn.ca., Ajani J; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burris H; Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA., Denlinger CS; Department of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Iqbal S; Divison of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA., Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Kim JH; Division of Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, South Korea., Lee KW; Department of Hematology and Medical Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea., Lin B; Section of Hematology-Oncology, Virginia Mason Medical Center, Seattle, WA, USA., Mehta R; Department of Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA., Oh DY; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea., Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Seol YM; Department of Internal Medicine, Pusan National University Hospital, Pusan National University College of Medicine, Busan, South Korea., Yang L; Jazz Pharmaceuticals, Palo Alto, CA, USA., Ozog MA; Jazz Pharmaceuticals, Palo Alto, CA, USA., Garfin PM; Jazz Pharmaceuticals, Palo Alto, CA, USA., Ku G; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Source: The Lancet. Oncology [Lancet Oncol] 2025 Jul; Vol. 26 (7), pp. 847-859. Date of Electronic Publication: 2025 Jun 02.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(25)00287-6